Amgen, Inc. (NASDAQ:AMGN) Shares Sold by F&V Capital Management LLC

Share on StockTwits

F&V Capital Management LLC cut its holdings in Amgen, Inc. (NASDAQ:AMGN) by 2.2% in the 4th quarter, HoldingsChannel reports. The fund owned 27,241 shares of the medical research company’s stock after selling 610 shares during the period. Amgen makes up 3.6% of F&V Capital Management LLC’s investment portfolio, making the stock its 7th largest position. F&V Capital Management LLC’s holdings in Amgen were worth $6,567,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Bangor Savings Bank increased its holdings in Amgen by 1.3% in the 4th quarter. Bangor Savings Bank now owns 3,361 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 42 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in Amgen by 2.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 1,883 shares of the medical research company’s stock valued at $364,000 after purchasing an additional 47 shares in the last quarter. Balentine LLC increased its holdings in Amgen by 36.1% in the 3rd quarter. Balentine LLC now owns 181 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Webster Bank N. A. increased its holdings in Amgen by 1.3% in the 4th quarter. Webster Bank N. A. now owns 3,870 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 48 shares in the last quarter. Finally, Clear Harbor Asset Management LLC increased its holdings in Amgen by 0.8% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 6,385 shares of the medical research company’s stock valued at $1,236,000 after purchasing an additional 49 shares in the last quarter. Institutional investors own 76.58% of the company’s stock.

NASDAQ:AMGN opened at $241.70 on Thursday. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. The firm has a 50-day moving average of $238.32 and a two-hundred day moving average of $208.80. The stock has a market cap of $142.60 billion, a P/E ratio of 16.78, a PEG ratio of 2.08 and a beta of 1.11. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $244.99.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, beating analysts’ consensus estimates of $3.53 by $0.13. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same period in the prior year, the company posted $3.69 EPS. As a group, equities analysts expect that Amgen, Inc. will post 14.58 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 14th will be given a $1.60 dividend. This is a boost from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 dividend on an annualized basis and a yield of 2.65%. The ex-dividend date is Thursday, February 13th. Amgen’s dividend payout ratio is presently 40.28%.

In other Amgen news, EVP Jonathan P. Graham sold 9,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $230.54, for a total value of $2,074,860.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total transaction of $91,566.25. Following the completion of the transaction, the director now directly owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,162 shares of company stock valued at $4,214,030. 0.25% of the stock is currently owned by corporate insiders.

Several brokerages recently issued reports on AMGN. Cowen increased their price target on Amgen from $253.00 to $277.00 and gave the company an “outperform” rating in a report on Thursday, December 19th. Credit Suisse Group increased their price target on Amgen from $235.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, December 13th. Morgan Stanley began coverage on Amgen in a report on Tuesday, December 17th. They issued an “overweight” rating and a $280.00 price target for the company. Goldman Sachs Group set a $243.00 price target on Amgen and gave the company a “buy” rating in a report on Monday, September 30th. Finally, Bank of America began coverage on Amgen in a report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Amgen has a consensus rating of “Buy” and an average target price of $235.39.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Do You Need a Fiduciary?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.